A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer.
W. K. Oh
Consultant or Advisory Role - Genentech; Sanofi
Research Funding - Genentech; Sanofi
M. D. Galsky
Consultant or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; GlaxoSmithKline; Pfizer
Research Funding - Celera; Viator
M. Barry
No relevant relationships to disclose
F. Fennessey
No relevant relationships to disclose
J. P. Richie
No relevant relationships to disclose
J. H. Hayes
No relevant relationships to disclose
R. S. Bhatt
No relevant relationships to disclose
M. Taplin
No relevant relationships to disclose
P. G. Febbo
Honoraria - Sanofi
R. W. Ross
No relevant relationships to disclose